Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using artificial ...

A real-world analysis reveals that tildrakizumab is highly effective and safe in patients with moderate-to-severe plaque ...

Today, Takeda announced positive topline results from 2 pivotal phase 3 trials of zasocitinib (TAK-279; Takeda), demonstrating superiority over placebo across key efficacy end points in adults with ...

Early Thursday, Takeda revealed top-line data for two pivotal phase 3 trials of its next-gen, highly selective oral tyrosine ...

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, ...

"Takeda to seek approval of plaque psoriasis pill on Phase III trial data" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...

In a combined network meta-analysis, infliximab and adalimumab had the greatest risk for serious infection in patients with plaque psoriasis.

The coprimary endpoints were the proportion of zasocitinib-treated patients achieving static Physician Global Assessment (sPGA) of clear (0) or almost clear (1) and Psoriasis Area and Severity Index ...

Compared to Sotyktu (deucravacitinib), which was approved by the FDA for plaque psoriasis in 2022 and brought in sales of ...

Shares of Takeda Pharmaceuticals rose after the Japanese pharmaceutical major announced positive results from clinical trials of its new treatment for plaque psoriasis. The stock climbed 4.3% in early ...